Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic...
Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer
About this item
Full title
Author / Creator
Publisher
London: BioMed Central Ltd
Journal title
Language
English
Formats
Publication information
Publisher
London: BioMed Central Ltd
Subjects
More information
Scope and Contents
Contents
Background Hypoxia is a key driver of cancer progression. We evaluated the prognostic impact of .sup.18F-fluoromisonidazole (FMISO) prior to treatment in patients with breast cancer. Methods Forty-four patients with stage II/III primary breast cancer underwent positron emission tomography/computed with .sup.18F-fluorodeoxyglucose (FDG-PET/CT) and F...
Alternative Titles
Full title
Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_71ea1e4447a34fafa8bdccd6ca52018a
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_71ea1e4447a34fafa8bdccd6ca52018a
Other Identifiers
ISSN
1465-542X,1465-5411
E-ISSN
1465-542X
DOI
10.1186/s13058-018-0970-6
